Evoke Pharma appoints Benjamin Smeal as Class II director
Evoke Pharma Inc
Board appoints Benjamin Smeal as Class II director effective October 18, 2024, with term expiring at 2027 annual meeting.
Smeal is a private investor; previously Associate Director at Willett Advisors (Michael Bloomberg's family office) and Senior Investment Analyst at Kenmare Management.
Appointment made pursuant to nominating rights in letter agreement with Nantahala Capital Management dated September 27, 2024.
Granted options to purchase 5,833 shares vesting in equal annual installments over three years; will receive cash compensation per non-employee director compensation program.
Smeal also appointed to Audit, Compensation, and Nominating and Corporate Governance Committees; Board determined independent per Nasdaq rules.
On October 18, 2024, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Benjamin Smeal to serve as a Class II director, effective October 18, 2024, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Benjamin Smeal was appointed as Class II director at Evoke Pharma Inc.
Action
appointed
Role
Class II director
Exact text from the filing
On October 18, 2024, pursuant to the amended and restated bylaws of Evoke Pharma, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Benjamin Smeal to serve as a Class II director, effective October 18, 2024, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.